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Abstract 
Background: In orthopedics, the treatment of implant-associated infections represents a high challenge. Especially, 
potent antibacterial effects at implant surfaces can only be achieved by the use of high doses of antibiotics, and still 
often fail. Drug-loaded magnetic nanoparticles are very promising for local selective therapy, enabling lower systemic 
antibiotic doses and reducing adverse side effects. The idea of the following study was the local accumulation of 
such nanoparticles by an externally applied magnetic field combined with a magnetizable implant. The examina-
tion of the biodistribution of the nanoparticles, their effective accumulation at the implant and possible adverse 
side effects were the focus. In a BALB/c mouse model (n = 50) ferritic steel 1.4521 and Ti90Al6V4 (control) implants 
were inserted subcutaneously at the hindlimbs. Afterwards, magnetic nanoporous silica nanoparticles (MNPSNPs), 
modified with rhodamine B isothiocyanate and polyethylene glycol-silane (PEG), were administered intravenously. 
Directly/1/7/21/42 day(s) after subsequent application of a magnetic field gradient produced by an electromagnet, 
the nanoparticle biodistribution was evaluated by smear samples, histology and multiphoton microscopy of organs. 
Additionally, a pathohistological examination was performed. Accumulation on and around implants was evaluated 
by droplet samples and histology.
Results: Clinical and histological examinations showed no MNPSNP-associated changes in mice at all investigated 
time points. Although PEGylated, MNPSNPs were mainly trapped in lung, liver, and spleen. Over time, they showed 
two distributional patterns: early significant drops in blood, lung, and kidney and slow decreases in liver and spleen. 
The accumulation of MNPSNPs on the magnetizable implant and in its area was very low with no significant differ-
ences towards the control.
Conclusion: Despite massive nanoparticle capture by the mononuclear phagocyte system, no significant patho-
morphological alterations were found in affected organs. This shows good biocompatibility of MNPSNPs after 
intravenous administration. The organ uptake led to insufficient availability of MNPSNPs in the implant region. For 
that reason, among others, the nanoparticles did not achieve targeted accumulation in the desired way, manifesting 
future research need. However, with different conditions and dimensions in humans and further modifications of the 
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Background
Implant-associated infections represent one dreaded 
complication in orthopedics. They occur as a result of 
contamination during or immediately after surgery or at 
later periods following hematogenic spread [1–3]. Num-
bers of implantations, in general, are growing because of 
an aging population, increasing obesity, and other predis-
posing factors [4–7]. In addition, worldwide rising bacte-
rial resistance against antibiotics [8–11] and further, the 
irreversible adhesion of bacteria and production of extra-
cellular matrix in biofilm formation on the implant sur-
face (infection cause) complicate a successful treatment 
[12–14]. This challenge is still accomplished by using high 
systemic doses of antibiotics for several months, accept-
ing adverse side effects [1, 15, 16]. Apart from intensive 
costs, this leads to high burdens for the patient as well as 
risks like amputation of the affected limb or even death 
in case of treatment failure [5, 17]. So far, different pre-
vention methods were studied avoiding bacterial adhe-
sion in combination with enhancing osseointegration [18, 
19] like surface modifications or antimicrobial coatings of 
implants [20–23].
As a treatment strategy in case of occurring implant-
associated infection in orthopedics, implant-directed 
magnetic drug targeting (ID-MDT) represents a possible 
approach to reduce systemic antibiotic doses, period and 
therefore side effects and probably the need of revision 
surgeries. Locally high and sufficient levels of antibiot-
ics might be achieved by loading magnetic nanoparticles 
with these antibiotics and target them by magnetic force 
towards the implant, followed by triggered drug-release 
[24–26].
In the last years there has been certain skepticism as to 
whether the various biomolecular targeting mechanisms 
(“vectorization” using certain receptors on target cells, 
antibody-antigen interactions, etc. [27, 28]) are actually 
effective and ultimately transferable to the human organ-
ism [29]. Accordingly, the question “Does nanomedicine 
have a delivery problem?” is discussed intensively [30]. 
Therefore, the necessity to develop new approaches is 
still present.
Magnetic nanoparticles are already versatilely used in 
research and partly in clinical issues for hyperthermia or 
drug delivery in tumor [31–35] and infection treatment 
[36, 37], as contrast agents for magnetic resonance imag-
ing [38–40], and others [41, 42]. The biocompatibility 
of certain magnetic nanoparticles with different com-
position, magnetic properties or size has already been 
published [43, 44]. Surface modifications with polyvinyl 
alcohol, polyethylene glycol (PEG, used in this study) 
or dextran, among others, can be performed to protect 
particles from rapid capture out of the bloodstream by 
the immune system, particularly by the mononuclear 
phagocyte system (MPS) [45–48]. Nevertheless, unde-
sired particle uptake into different organs occurs, for 
example into the lung, liver, and spleen following intrave-
nous administration [43, 49] and has to be minimized. To 
our knowledge, no studies were performed dealing with 
in vivo extravasation of magnetic nanoparticles towards 
the surface of the magnetic source. However, it is pre-
sumed that an external (electro-) magnetic field alone is 
insufficient to attain accumulation of magnetic nanopar-
ticles in deeper body regions [50, 51]. For that reason, the 
here presented study used a magnetizable plate as a rep-
resentative for orthopedic implants/prostheses as a sec-
ond source of a magnetic field. When magnetized by the 
external magnetic field it will intensify the existing field 
gradient [25, 52].
The design of this study is significantly different from 
previous publications since the applied therapy approach 
will enable a locally effective treatment at any time and 
in any body region, making the normally inaccessible 
implant surface reachable for therapeutics.
Our preliminary in vivo experiments demonstrated the 
detectability of fluorescence-labelled magnetic nanopo-
rous silica nanoparticles (MNPSNPs) after subcutaneous 
administration onto inserted magnetic test and paramag-
netic control implants [53]. The study presented here 
dealt with follow-up experiments which focused on the 
MNPSNP performance after intravenous application. 
Three central problems were examined in  vivo: Firstly, 
the MNPSNPs were supposed to be biocompatible. This 
property was examined for a duration of up to 42 days. 
Secondly, it was hypothesized that the MNPSNPs were 
available in the implant area to a large extent due to 
PEG-surface with associated prolonged blood half-life, 
as well as enabled extravasation of MNPSNPs assum-
ing comparably increased permeability as reported for 
similar but smaller nanoparticles in a study by Qiu et al. 
[54]. Thirdly, based on our preliminary results, it was 
assumed that ferritic steel 1.4521 implants should attract 
significantly higher numbers of magnetic nanoparticles 
nanoparticles, this principle should enable reaching magnetizable implant surfaces at any time in any body region for 
a therapeutic reason.
Keywords: Magnetizable implant, Drug targeting, Magnetic nanoporous silica nanoparticles, PEG, Organ 
accumulation, Ferritic steel, Mouse model, In vivo
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than paramagnetic titanium alloy (Ti90Al6V4) implants 
in  vivo. To verify these hypotheses, test and control 
implants were inserted subcutaneously followed by intra-
venous administration of fluorescent MNPSNPs and 




The in  vivo experiments were authorized according to 
the German Animal Welfare Act (registration number: 
33.12-42502-04-13/1103) and performed in 50  female 
BALB/cJHanZtm mice with an average body weight 
(BW) of 28 ± 2.4  g. Mouse husbandry was organized in 
groups of up to five mice with a 14 h/10 h-day/night cycle 
and free access to food (Maintenance diet, Altromin Spe-
zialfutter GmbH & Co. KG, Germany) and tap water.
Ferromagnetic implants (n = 50, 6 ×  2 ×  1  mm3, fer-
ritic stainless steel 1.4521, Outokumpu Nirosta GmbH, 
Germany) with high relative permeability and low resid-
ual magnetization (remanence) were inserted subcu-
taneously. Each mouse received one implant at the left 
hindlimb, parallel to the femur. Paramagnetic titanium 
alloys Ti90Al6V4 with the same dimensions (n = 50, 
GoodFellow, England) were similarly inserted in the con-
tralateral hindlimb serving as a negative control.
For the surgical procedure anesthesia was performed 
by intraperitoneal injection of a ketamine-xylazine-
mixture (70  mg ketamine/kg  BW (Wirtschaftsgenos-
senschaft deutscher Tierärzte eG, Germany) and 7  mg 
xylazine/kg  BW (CP-Pharma Handelsgesellschaft mbH, 
Germany)), occasionally prolonged by midazolam (5 mg/
kg BW, i.p., ratiopharm GmbH, Germany). Peri-operative 
analgesia was ensured by subcutaneous administration 
of meloxicam (1 mg/kg BW, CP-Pharma Handelsgesells-
chaft mbH, Germany). The implant was inserted after 
skin incision and the wound was closed by two horizontal 
mattress sutures with  PROLENE® 6-0 (Johnson & John-
son Medical GmbH Ethicon Germany).
After the surgical procedure, 420  µg MNPSNPs dis-
persed in 0.1  mL sodium chloride were injected intra-
venously in the mouse’s tail vein, resulting in a mass 
concentration of approx. 230  µg MNPSNPs/mL blood. 
The used MNPSNPs have a  Fe3O4-core, a 50  nm thick 
silica shell, an average diameter of approx. 112 ± 16 nm, 
a spherical shape, and superparamagnetic properties. 
Furthermore, the nanoparticles are negatively charged 
(zeta-potential: − 30 mV) and modified with rhodamine 
B isothiocyanate (RITC) enabling detection and polyeth-
ylene glycol-silane (PEG) prolonging half-life in blood.
As immediately following final step, a magnetic field 
was applied at both hindlimbs (strength approx. 1.8  T, 
EM2, Magnet-Messtechnik J. Ballanyi, Germany) for 
10  min. The detailed surgical procedure and magnetic 
field application, as well as the synthesis and characteri-
zation of the MNPSNPs, have already been described by 
Janßen et al. [53].
To obtain an overview of MNPSNP distribution in the 
body, mice were euthanized by cervical dislocation at dif-
ferent time points after MNPSNP injection: 15 min, 1, 7, 
21, 42 days (group 0, 1, 7, 21, 42), ten mice per group. For 
evaluation, the implants were removed, and blood, urine 
and organ samples were taken. During the postopera-
tive follow-up, the mice were examined clinically every 
day for the first week and three times per week afterward 
(except for group 0).
Biodistribution of MNPSNPs detected by fluorescence 
analysis and pathological changes
Blood and urine as well as organ material from lungs, 
liver, spleen, kidneys, and exemplarily from the brain 
(0.4  ×  0.3  ×  0.3  mm3, respectively) were spread out 
homogeneously onto slides, the so-called blood, urine, 
and organ smear samples. Furthermore, 5  µm thick 
histological slices of formaldehyde 4%-fixed and par-
affin-embedded organs including muscle, subcutis, 
and skin of the hindlimbs (area of former implant loca-
tion), exemplarily of the heart muscle, tail vein, Vena 
cava caudalis and its branches, Lnn. iliaci, poplitei and 
subiliaci were produced. Blood, urine, and organ smear 
samples as well as histological slices were analyzed 
by fluorescence microscopy (Axioskop 40, Carl Zeiss 
AG, Germany) using 400fold magnification, a red fil-
ter for characteristic detection (filter set  20, Excitation 
BP 546/12, Beam Splitter FT 560, Emission BP 575-640, 
Carl Zeiss AG, Germany) and a green filter (filter set 44, 
Excitation BP  475/40, Beam Splitter FT  500, Emission 
BP  530/50, Carl Zeiss AG, Germany) for the control of 
autofluorescence.
Ten fields of view of each blood, urine, and organ 
smear sample were scored regarding the presence of the 
irregularly shaped and different sized MNPSNP clusters 
(Table 1) and summed up to a total score, as previously 
described [53]. For the verification of these results, the 
presence of MNPSNP clusters in unstained histologi-
cal slices was analyzed descriptively with regard to its 
quantity, size, shape, localization, distribution, asso-
ciation or pattern. Hematoxylin–eosin (H.E.) stained 
histological slices of all mentioned organs were descrip-
tively evaluated for pathological changes and even-
tually detectable MNPSNP clusters by an unblinded 
investigator as well as an investigator unaware of the 
treatment assignment. Additionally, exemplary fresh 
lung, liver, spleen and kidney samples from mice in 
groups 0, 1, and 7 were sprinkled with 0.1% riboflavin 
(Sigma Aldrich) in phosphate-buffered saline for 5 min 
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for further examination with a multiphoton microscope 
(MPM200, Thorlabs, Germany). A tunable femtosecond 
laser system (titanium-sapphire laser, Chameleon Ultra 
II, Coherent Inc., USA) at a wavelength of 850 nm and 
an objective with a numerical aperture of 1.05 (Olym-
pus XLPLN25WMP2, Germany) were used for imaging.
Results were additionally compared with physiologi-
cal, untreated organ samples which were received from 
mice that have been killed according to §4 of the Ger-
man Animal Welfare Act and reported according to the 
legal requirements.
Detection of targeted enrichment of MNPSNPs 
on the implant surface
The ferritic steel and titanium alloy explants were put 
into 100 µL A. dest., respectively, vortexed and treated 
in an ultrasonic bath to detach eventually accumulated 
MNPSNPs. This procedure was repeated for another 
two times, always transferring the treated explant into 
new A.  dest. The three resulting suspensions for each 
explant were dropped on slides, five drops per suspen-
sion, so-called droplet samples. With the same settings 
for fluorescence microscopy as described for the blood, 
urine, and organ smear samples, one visual field for 
peripheral regions and three visual fields of the mid-
dle region of each dried drop were scored regarding 
the quantity and size of MNPSNP clusters (Table  1). 
Finally, a total sum score of suspensions 1–3 was cal-
culated (possible score range per suspension: 0–700; in 
total: 0–2100).
Afterward, the surfaces of the explants were evalu-
ated by fluorescence microscopy with the same set-
tings. Possibly remaining MNPSNPs were descriptively 
assessed regarding distribution and quantity.
More detailed descriptions of production and evalu-
ation of organ smear and droplet samples have already 
been described by Janßen et al. [53].
Statistics
The final evaluation and statistical analysis included a 
total of 41 animals. Nine animals dropped out for final 
evaluation due to terminal circulatory collapse dur-
ing or after anesthesia (n = 4) or failed injection of 
MNPSNPs (n = 5). The following number of mice for 
each group was evaluated:  n0 = 8,  n1 = 9,  n7 = 9,  n21 = 6, 
 n42 = 9.
Statistical analysis was performed using  SPSS®  25 
(IBM, USA). Nonparametric tests (Kruskal–Wallis/
Mann–Whitney-U) were performed in blood, organ 
smear, and droplet samples due to ordinal evalua-
tion methods. If p < 0.05, differences between the time 
groups (blood, organ smear and droplet samples) and 
additionally between the implant materials (droplet 
samples) were considered statistically significant.
Results
Clinical examination of mice in the follow‑up periods
The area of wound suture was mildly swollen, red-
dened and scabbed for the first days after surgery. No 
other clinical changes were observed. Furthermore, 
the mobility of the hindlimbs was not restricted by 
the implants. During the postoperative follow-up, no 
mouse lost temporary more than 5% of BW.
Two distributional patterns of MNPSNPs in organs were 
detected via fluorescence microscopy
All applied methods, including smear samples, fluores-
cence microscopy of histological slices and multipho-
ton microscopy (MPM) of exemplary organs, showed 
congruent results. The summed scores of blood and 
smear samples are shown in Fig. 1 and its significances 
are listed in Table 2.
The evaluation of MNPSNP quantity in blood and dif-
ferent organs revealed two distributional patterns: (1) a 
high MNPSNP concentration immediately after intra-
venous injection followed by a significant drop and (2) 
a high concentration followed by only slow decrease. 
The first pattern was observed in blood, heart muscles, 
lungs, kidneys, and brains. The highest MNPSNP con-
centration existed in group 0, respectively, followed by 
a highly significant decrease towards zero until the next 
day. The blood samples, as well as histological slices of 
the tail vessels, Vena cava caudalis and its branches, 
contained large amounts of MNPSNP clusters (Fig. 2a–
c). In group  1 some vessels showed clusters wide-
stretched in the area of vascular walls as if they were 
coating these. One very small caliber vessel was filled 
with clusters even in group 7. Exemplarily sliced hearts 
showed occasional, diffuse and different-size MNPSNP 
clusters in the muscle up to one day.
Table 1 Score for semiquantitative evaluation of MNPSNP 
distribution and  accumulation of  blood, urine, organ 












Very small 0 1 2 3 5
Small 0 2 3 4 6
Medium 0 3 4 5 7
Large 0 4 5 6 8
Very large 0 5 6 7 9
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Partly strong autofluorescence of various cells mas-
sively impeded MNPSNP detection in the brain. Solely 
in group 0 single, rare and little to large clusters could 
be identified in histological brain samples and also in 
exemplarily taken brain smear samples (Fig. 2d–f ).
The lung of group 0 showed by far the highest score of 
all organ samples (Fig.  1, Table  2). Histologically, partly 
high-grade, diffuse MNPSNP-characteristic fluorescence 
of different sizes and shape were found in alveolar septa 
(Fig. 3b). In total, the entire lung was affected moderately 
to severely. In group 1 MNPSNPs became sporadic and 
rare (Fig.  3d–f). Sliced corresponding lymph nodes in 
groups 0 and 1 very rarely contained MNPSNP clusters.
There was no difference observed between right and 
left kidneys. In group  0, a low amount of mostly large 
clusters was detected in a lot of glomeruli (Fig.  4b), as 
Fig. 1 Box-and-whisker plots of the summed score regarding quantity of MNPSNP clusters in blood and organ smear samples per group (0, 1, 7, 21 
and 42). The boxes represent the 25th to 75th percentiles, the black solid lines indicate the median values and circles show outliers. For statistical 
significances, see Table 2
Table 2 Overview of  statistical significances (exact p value) corresponding to  Fig.  1 (blood and  organ smear samples) 
and Fig. 7 (droplet samples) created by Mann–Whitney-U-Test
Groups 0, 1, 7, 21 and 42, *p < 0.05, **p < 0.01, ***p < 0.001
Compared groups Smear samples Droplet samples
Blood Lung Kidney Liver Spleen Ferritic steel Titanium alloy
0–1 *** *** *** * ** ***
0–7 *** *** *** ** **
0–21 ** ** * ** **
0–42 *** *** *** *** *** * *
1–7 ** * ** *
1–21 ** ** * ** *** ***
1–42 ** *** *** *** *** ***
7–21 ** * ** *** **
7–42 ** *** *** *** ***
21–42 ** *** ***
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well as diffuse, small clusters in the areas of tubules in 
medulla and cortex. At later periods, clusters were occa-
sional to rare. Corresponding smear samples corrobo-
rated this pattern but showed a small peak in group  21 
with a significant decline towards group  42 (Fig.  1, 
Table  2). Autofluorescence of the tissue moderately 
impeded the detection. In the images of MPM, clusters 
were detectable in the lumens and in group 1 and 7 very 
small clusters were finely distributed in tubule epithelium 
or in lumens (Fig.  4c, d). MNPSNP detection in urine 
samples for excretory behavior was totally impossible due 
to extreme autofluorescence.
The second pattern was a high MNPSNP concentra-
tion in group 0 with a slow decrease towards later time 
groups, observed in liver and spleen (Figs. 5, 6). Histolog-
ically, livers contained mild to moderate, diffuse, differ-
ently sized MNPSNP clusters which were not observed 
in core areas of hepatocytes. Finally, in group  42 they 
occurred occasionally. In the red splenic pulp (mostly 
in marginal sinuses and directly around the follicles), 
MNPSNP-characteristic fluorescence was low-graded, 
diffuse, oligofocal highly concentrated, in group  7 still 
mild to moderate and even in group  42 detectable. In 
both organs, clusters were mostly single or grouped 
together in oval shape, which was clarified by images of 
MPM. The high score values of hepatic and splenic smear 
samples in group  0, even if lower than lung values, just 
slowly decreased and as late as in group 42 significantly 
declined (Fig. 1, Table 2).
Finally, it should be noted that the exact localization of 
clusters—whether present in a tiny blood vessel/capillary 
or in the heart muscle/lung septa/brain tissue itself—
could not be spotted.
Targeted accumulation of MNPSNPs on the implant 
and in its surrounding tissue
MNPSNP clusters on implants and in the surround-
ing tissue were already detected directly after magnetic 
field application (group  0), followed by a significant 
increase after one day (group 1) and a decline of almost 
Fig. 2 Detection of MNPSNP clusters (→) via fluorescence microscopy in blood (a–c) and brain (d–f) smear samples (a, d) and histological slices (b, 
c, e, f). a Blood with many MNPSNP clusters, group 0; b small blood vessels in a tail with large amounts, group 0; c blood vessel with clusters lining 
its wall, group 1; d brain with one large cluster, group 0; e brain with a single cluster, group 0; f see e, green filter for control and demonstrating 
autofluorescent cells (circles). All scale bars: 50 µm
Page 7 of 18Janßen et al. J Nanobiotechnol           (2020) 18:14 
exponential character until day 42. There were no signifi-
cant differences between ferritic steel and titanium alloy 
except for group 42 (*). The scores of droplet samples are 
shown in Fig. 7 and its significances are listed in Table 2.
Regarding the presence of still remaining MNPSNPs 
on the explants, sometimes very little clusters cannot be 
excluded because of impeding autofluorescence of adher-
ent tissue/cells, especially on skin-facing sites or focal 
areas of the ferritic implant material itself. In group  0 
and 7, only on ferritic steel explants single remaining lit-
tle clusters were detected. On the contrary, in group 1 a 
lot of titanium and most ferritic steel explants contained 
occasional, diffuse, small clusters. In a piece of adher-
ent tissue on one ferritic plate a moderate amount of 
MNPSNPs was found. No characteristic fluorescence was 
observed in group 21 or rather 42.
Histological slices of subcutis where the implant had 
been located showed diffuse, single, up to large MNPSNP 
clusters in surrounding muscle, connective tissue, and 
subcutaneous fat tissue until 7  days via fluorescence 
microscopy. Thereafter, detection was improbable. If the 
interface was cut, marginal to moderate amounts were 
found distributed also in inflamed tissue and partly asso-
ciated to cells in group  1. Differences between the left 
and right hindlimbs could not be observed (Fig. 8a, b).
In individual cases, corresponding lymph nodes (Lnn. 
iliaci, Lnn. poplitei) contained single little to large clus-
ters only in group 0 and 1 (Fig. 8c). Strong autofluores-
cent cells impeded a definite detection of partly weak 
fluorescent MNPSNP clusters. Therefore, the presence of 
very small clusters cannot be excluded.
No pathomorphological changes in most inner organs 
and confirmed MNPSNP detection via H.E. staining
The results of both pathological reports were consist-
ent. MNPSNPs were detected in H.E. stained samples 
as irregular shaped, homogenously brown particles. 
Solely in group  0 MNPSNPs were occasionally found 
in tail vessels, Vena cava caudalis and its branches, as 
well as rarely in the glomeruli of kidneys. In the lungs, 
many MNPSNP clusters were detected in alveolar septa 
Fig. 3 Lung. Detection of MNPSNP clusters (→) in smear samples (a, d), histological slices (b, e) via fluorescence microscopy and fresh tissue via 
multiphoton microscopy (MPM; c, f). a–c Group 0 with moderate to high amounts of MNPSNP clusters of different size and shape in alveolar septa 
b; d–f group 1 with sporadic to rare clusters. All scale bars: 50 µm
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in group  0 (Fig.  9) but also some clusters in group  1. 
Apart from the detection of MNPSNPs, no significant 
pathomorphological alterations were found in the kid-
neys, spleens, brains, lymph nodes, and heart muscles. 
In some animals a mild, multifocal, lymphohistiocytic 
inflammation in lung and/or liver was detected at all 
time points. Similar alterations in the subcutis at both 
implantation sites (right and left hindlimbs) were 
detected ranging from acute inflammatory changes 
consisting of fibrin intermingled with few neutro-
phils and macrophages in group  0 and 1 to mild 
lymphohistiocytic inflammation and fibrosis in the lat-
est groups (Fig. 10).
Discussion
In the present study, three main hypotheses were exam-
ined. Firstly, it was assumed that systemically admin-
istered MNPSNPs are physiologically harmless to the 
body. Secondly, it was hypothesized that MNPSNPs are 
available in the implantation area. And thirdly, based on 
the results of previous in  vitro and in  vivo studies [26, 
53, 54], an externally magnetized ferromagnetic implant 
material was supposed to be able to accumulate these 
Fig. 4 Kidney. Fluorescence detection of MNPSNP clusters (→) of group 0 (a–c) and group 1 (d). a Smear sample with a single large cluster; 
b histological slice with single large clusters in some glomeruli; c, d Images of MPM with clusters in the tubule lumens (c) and finely distributed in 
tubule epithelium (d). All scale bars: 50 µm
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nanoparticles at the implant surface in higher concen-
trations than the control. This would mean a safe use of 
MNPSNPs as future drug carrier system for implant-
associated infection treatment.
According to the first hypothesis, we can state that 
MNPSNPs are biocompatible and do not seem to influ-
ence the body’s physiology, at least in the observed 
time interval of up to 42  days. No clinical changes of 
mice and no significant pathomorphological altera-
tions in histological examination were observed which 
coincides with different nanoparticles in the literature 
[43, 44, 55]. The mild, multifocal inflammatory altera-
tions in lungs and/or livers were supposed to be not 
MNPSNP-associated since they occurred in all groups 
infrequently and lesions were not associated with 
MNPSNP clusters.
Fig. 5 Liver. Detection of MNPSNP clusters (→) in smear samples (a, d, g), histological slices (b, e, h) via fluorescence microscopy and fresh tissue 
via MPM (c, f). a–c Group 0, d–f group 7, mild to moderate, diffuse, differently sized clusters, partly grouped together in oval shape, respectively; 
g, h group 42, occasional, diffuse clusters. All scale bars: 50 µm
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Regarding the second hypothesis, the significant 
decline of MNPSNPs in group  0 in blood samples and 
high amounts in examined organs, especially the lung, 
demonstrate a fast capture. Concerning the biodistribu-
tion of MNPSNPs after intravenous injection, the lung 
with its very small capillaries and phagocytose system 
represents the first bottleneck for nanoparticles and an 
undesired direct entrapment probably by different lung 
macrophages or monocytes [49, 56, 57]. The detection 
of MNPSNP clusters in the lung was almost restricted 
to 15  min post intravenous injection. The formation 
of emboli in the sense of passive accumulation of clus-
ters due to very small vessel diameters [58, 59] and step 
by step disappearance following blood stream seems to 
be very unlikely due to missing relating histopathologi-
cal alterations like infarctions. Whereas a very similar 
Fig. 6 Spleen. Detection of MNPSNP clusters (→) in smear samples (a, d, g), histological slices (b, e, h) via fluorescence microscopy and fresh tissue 
via MPM (c, f). a–c Group 0, mild to moderate, diffuse, differently sized clusters, partly grouped together in oval shape; d–f group 1, slightly less than 
group 0; g, h Group 42, rare to occasional, diffuse clusters. All scale bars: 50 µm
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observation was made by Al-Jamal et  al. in a magnetic 
tumor targeting model where high amounts of PEGylated 
nanocapsules (comparable size to MNPSNPs, different 
composition; 1  h after i.v. injection) disappeared to a 
large extent during further 3 h [43], Mojica Pisciotti et al. 
obtained higher values of PEGylated magnetite parti-
cles (comparable size, no silica shell; i.v.) in lung than in 
liver still after 24 h. The reason for the much longer pres-
ence in the lung in their study is probably related to the 
fact that the externally applied permanent magnet was 
not far away, placed on the tumor site (flank) during the 
24 h-time period [60].
In contrast to the lung, accumulation of MNPSNPs in 
the liver and in the red pulp of the spleen can be attrib-
uted to a passive particle accumulation due to higher 
permeability of sinusoidal capillaries (100–1000  nm 
pore size [61, 62]) additional to active phagocytosis of 
macrophages [63]. Estevanato et al. showed that already 
one hour after intravenous administration Kupffer cells 
were actively involved in capture of dextran functional-
ized magnetite nanoparticles (approx. 10  nm in diam-
eter) enclosing them in phagolysosomes [64]. After a 
few months, Perls reaction in the area of these dextran 
nanoparticle clusters demonstrated Fe(III) release which 
would pass over to the physiological iron metabolism 
[64]. The significant decrease around the 42nd day in the 
present study probably also indicates beginning degrada-
tion of MNPSNPs.
Excretion of MNPSNPs, which is assumed mainly by 
urine and negligibly by faeces [43], might be the reason 
for the fine distribution in the tubules (epithelium and 
lumen) of kidney at later time points, which could be vis-
ualized by MPM. Histological examination only showed 
MNPSNP clusters in small quantities in the glomeruli of 
the kidneys and tubule-associated in group 0. Natarajan 
et al. observed higher amounts of 100 nm radioimmuno-
nanoparticles in kidneys than in spleens after 48 h [65].
Detected MNPSNP clusters in the brain might be spo-
radically located inside larger blood vessels [66, 67]. It 
is assumed that they did not cross the blood brain bar-
rier and were transported via blood flow to other organs 
being trapped there [68–70]. In addition, MNPSNPs 
were not supposed to cause any damage in the brain 
Fig. 7 Box-and-whisker plots of the evaluation of droplet samples 
representing MNPSNP mass accumulated on the surface of ferritic 
steel and titanium alloy implants. Summed score respectively 
is shown for the examined groups 0, 1, 7, 21 and 42. The boxes 
represent the 25th to 75th percentiles, the black solid lines 
indicate the median values and circles show outliers. For statistical 
significances, see Table 2
Fig. 8 Detected MNPSNP clusters (→) in subcutis with former implant location (*) of the left (a) and right hindlimb (b) and in a corresponding 
lymph node (c) of group 1. Scale bar: 50 µm
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[71–73]. Clusters in heart muscles were most likely 
located intravascularly.
In conclusion, intravenous administration of RITC-
labeled MNPSNPs (420  µg per animal) does not seem 
to affect mouse physiology although temporary accu-
mulation in different organs occurs. The combination 
of silica shell, PEG and size led to similar distribution as 
published for other nanoparticles [43, 44, 60, 63–65]. The 
PEGylation in order to prolong the half-life period in the 
blood and to avoid the observed capture in inner organs 
by the MPS [74] was therefore not adequate enough [75, 
76]. This reduces distinctly the availability of nanopar-
ticles in the blood stream and therewith hinders their 
accumulation at the desired location.
This might be one reason why the third hypothesis that 
a significant higher number of MNPSNPs can be accu-
mulated at ferromagnetic implant surfaces in a magnetic 
field gradient could not be confirmed. In in vitro experi-
ments from Janßen et  al. (tube system filled with circu-
lating MNPSNP suspension), it was assumed that the 
accumulated MNPSNP mass in the test area in passes 
without ferromagnetic material was caused by the exclu-
sive power of the electromagnetic field. A slight mass 
increase was observed due to the use of ferromagnetic 
plate inducing a magnetic gradient [53] which was also 
described as a key factor for augmenting magnetic force 
[77]. The in vivo setup was expected to offer an enhanced 
opportunity to assess the magnetic influence of the fer-
ritic material. The first reason for this assumption is the 
difference between tube and blood vessel diameter and 
related flow velocities. While 12.2  mm/s were used in 
the in  vitro trial [53], much lower flow velocities exist 
in vivo in small animals (~ 1 mm/s [78–80]) and even in 
the human capillaries (< 1  mm/s [81–84]). In general, it 
is stated that the lower the flow velocity, the higher the 
amount of accumulated nanoparticles [26, 50, 85, 86]. 
The second reason is the higher frequency of circulating 
MNPSNPs passing the implantation area. In theory, with 
a cardiac output of approx. 15 mL/min [87, 88] an aver-
age total blood volume of 1.8 mL [89] (inclusive intrave-
nous injection volume) from treated mice will be pumped 
around over 80 times in 10 min. In the above mentioned 
in vitro setup from Janßen et al., where MNPSNPs were 
trapped by similar implants and magnetic field forces 
in a circulating tube system, only one twentieth of the 
value was reached [53]. This means a much higher prob-
ability for MNPSNPs in the blood to be trapped by 
magnetic force in  vivo. Of course, this simplified calcu-
lation is not directly transferable to the in vivo situation, 
which is influenced by numerous factors, but shows that 
aspects other than physical had probably reduced the 
accumulation.
The ferritic steel implant only shows a tendency of 
increased accumulation compared to the titanium alloy, 
which is far from clinical need. A nanoparticle distribu-
tion is presumed which is predominantly passive and 
not actively supported by the implant. Probably the ves-
sels were temporarily leaky due to surgical insertion of 
implants and MNPSNPs were led by blood (unspecific, 
heterogeneous distribution) and the exclusive power of 
electromagnetic field and its gradient, which was car-
ried out at both implant materials. The latter could 
also explain MNPSNP clusters between the muscle fib-
ers in both hindlimbs. The decline after one day can be 
explained by the removal of MNPSNPs by the mono-
nuclear phagocyte system (MPS). Compared to scores 
described by Janßen et al. where MNPSNPs were detected 
on the implant surface in considerable quantities even 
Fig. 9 MNPSNP cluster (→) detection in H.E. stained histological slices in a blood vessel (a), alveolar septa (lung, b) and glomeruli (kidney, c). All 
scale bars: 50 µm
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7 days after subcutaneous injection around the implants 
[53], the value 7 days after intravenous administration is 
negligible. This significant difference is less due to phago-
cytosis by the MPS, but rather due to low quantities at 
the beginning after intravenous application, shown by 
higher but overall low score values in group 0. However, 
what was caused by the immune system are the inflam-
matory reactions and formation of fibrosis which were 
found around the implants. It is a characteristic response 
towards the implant as foreign body [90] and was also 
shown in the earlier examinations by Janßen et  al. after 
subcutaneous administration of MNPSNPs [53]. Accord-
ing to biocompatibility, ferritic steel implants as a not 
approved material for in  vivo application, seem to be 
promising for future designing and investigations due to 
missing significant difference towards the titanium alloy.
Another possible reason for the inadequate target-
ing result is an insufficient vascular permeability [91]. In 
healthy muscle tissue the continuous capillary pore size 
is about 6 nm [61, 92, 93]. It is unlikely that MNPSNPs 
of our size could widen these pores [94, 95] by means 
of pressure due to magnetic force and pass through by 
paracellular way. Qiu et  al. observed that 33  nm PEG-
coated nanocrystals were endocytosed by endothelial 
cells, which led to intracellular magnetic force while an 
external magnetic field was applied. This force caused 
a disruption of adherens junctions and consequently 
increased endothelial permeability [54]. If this scenario 
had occurred in the here presented study and inter-
endothelial clefts were wide enough, residual nanopar-
ticles in the blood would have been able to extravasate. 
Although MNPSNPs are negatively charged [96, 97] 
and hydrophilic [98] due to PEG-coating, pinocytosis 
(< 500  nm size [99]) could occur, albeit more slowly. In 
addition, caveolae-mediated endocytosis which exists in 
muscles, among others [100], could have functioned as 
transcytosis pathway [101, 102]. However, in the clinical 
scenario of implant infection, increased endothelial per-
meability is present [103, 104] and therewith overcoming 
the first barrier, the transfer from blood vessel into the 
infected tissue surrounding the implant, should probably 
occur.
In stent models with a magnetic source inside the ves-
sel as well as in investigations towards particle behavior 
in a vessel with close externally applied magnetic field 
(simulation or in vitro, respectively) the following pro-
portionalities were observed: The higher the magnetic 
field strength and the gradient, the particle size and 
concentration and the lower the fluid flow velocity and 
the distance between vessel and external magnet, the 
higher the capture efficiency of the magnet [50, 85, 86, 
105–108]. In the here presented study, magnetic field 
application time of 10  min might have been too short 
Fig. 10 Pathological findings in the subcutis at the implantation site 
(*). a Mild focal hemorrhage with fibrin extravasation, few neutrophils 
and macrophages, group 0; b low numbers of neutrophils and 
macrophages with fibrin, group 1; c mild lympho-histiocytic 
inflammation, group 7; d, e mild lympho-histiocytic inflammation 
with fibrosis, group 21 (d) and 42 (e), respectively. H.E. staining, all 
scale bars: 50 µm
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[54] or the produced magnetic field strength was insuf-
ficient [77, 109–111] although many in vitro and in vivo 
studies used lower magnetic field strength than 1.7  T 
for successful targeting [43, 60, 85]. Regarding the per-
meability of the ferritic steel, the implant was possibly 
inadequate to enhance the magnetic field strength of 
the electromagnet and to build up a stronger gradient 
in the way needed. The relatively small geometry of the 
implant could likely drastically lower the usually higher 
permeability. In the case that the electromagnetic field 
is the dominating magnetic force, it is conceivable that 
MNPSNPs align themselves in this field [112] instead of 
being attracted by a point source and leave the region of 
interest after field removal. Compensating, the distance 
between the used ferritic implant and a blood vessel in 
muscle tissue or skin is about a few micrometers or less, 
so very small [105]. Furthermore, diameter and magne-
tophoretic force of nanoparticles enormously influence 
the accumulation [113, 114] because particles have to 
oppose many forces like blood flow velocity (see above), 
gravitation, among others [77, 110, 115]. Particle inter-
actions with other particles or collision with blood cells 
and the type of protein corona might also affect the 
administered MNPSNPs [77, 96, 110, 115, 116]. On the 
contrary, no significant influence on capture efficiency 
was expected from the thickness of silica- and PEG-
coatings of MNPSNPs according to computer simula-
tions investigated by Lunnoo and Puangmali [113].
Although clinically relevant accumulation of 
MNPSNPs at the implant surface could not be shown 
in the present study, this concept constitutes a great 
potential because several factors are different in the sce-
nario of an infected implant in humans. When implant-
associated infection occurs, the vascular permeability 
of surrounding tissue is automatically enhanced [104] 
and nanoparticles should be able to accumulate in the 
implant region. Accordingly, the significant difference 
towards the control implant will arise from MNPSNPs 
overcoming the distance between blood vessel and 
implant surface only in case of occurring magnetic field 
gradient. Further research work, however, is needed to 
prevent nanoparticle clearance by the MPS. Therefore, 
apart from PEG, additional functionalization or coat-
ings are necessary, e.g. binding of CD47 to the surface 
of the nanoparticles [76, 117, 118]. Another focus is 
the enhancement of magnetic properties by equip-
ping nanoparticle cores with higher iron content [43] 
and design larger implants out of a highly permeable, 
remanent ferromagnetic material [26], probably with 
additional surface coatings [52]. With the manifold 
changes it must be considered, that superparamagnet-
ism and a suitable size of nanoparticles are continu-
ously guaranteed.
Conclusion
Altogether, the intravenous application of fluorescent 
MNPSNPs in mice was well biocompatible, showing 
no clinical or significant pathomorphological altera-
tions of inner organs up to 42  days after administra-
tion. In parallel, significant targeting of MNPSNPs from 
the blood to a subcutaneous magnetized ferritic steel 
1.4521 implant by an externally applied magnetic field 
(electromagnet) was not achieved. This was especially 
attributed to high capture of MNPSNPs by MPS in 
lung, liver and spleen. Other factors contributing to the 
lack of MNPSNP accumulation at the implantation site 
might be the insufficient permeability of blood vessels 
in the target region and probably the implant dimen-
sions and therewith magnetic properties in this in vivo 
model.
Although the goal of sufficient accumulation could 
not be reached, particular challenges concerning, e.g., 
improvement of particle properties for better biodistri-
bution or magnetic implant properties for higher accu-
mulation at the surface could be carved out for further 
studies. In this way, the presented study lays a valuable 
basis for the local treatment of orthopedic implant-
associated infections after systemically administered 
nanoparticles by ID-MDT in the future.
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